Thrombotic complications from COVID-19 are now well known and contribute to significant
morbidity and mortality. Different variants confer varying risks of thrombotic complications …

The pathogenesis of coronavirus disease (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS‑CoV‑2), is complex and involves dysregulated immune …

Molnupiravir, dexamethasone, ertapenem, and remdesivir are among the most frequently co-
prescribed drugs used for COVID-19 virus treatment. For the first time, a simple isocratic …

Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …

A high rate of thromboembolism and a high risk of death have been reported regarding
hospitalized patients with coronavirus disease 2019 (COVID-19). Recently, we noticed that …

Since severe acute respiratory syndrome coronavirus 2 led to a world pandemic, extensive
research has been conducted to identify its characteristics and form an appropriate …

Infection with the SARS-CoV-2 virus (COVID-19 disease) can cause a wide range of clinical
situations–from an asymptomatic state to fatal outcomes. In cases of serious clinical …

The coexistence of diabetes mellitus (DM) and tuberculosis (TB) presents a significant
global burden, with DM being recognized as a major risk factor for TB. This review …

SARS-CoV-2 can directly or indirectly damage endothelial cells. Endothelial injury,
especially phosphatidylserine (PS) exposure on the outer membrane of cells, can more …

Background: Hospitalized patients with COVID-19 have shown a significant occurrence of
thromboembolism and a heightened risk of death. It remains unclear whether factor Xa …